High Levels Of Testosterone Increases Appetite For Risk In Women; High Levels Connected To Choice Of Riskier Careers
The battle of the sexes rages on, this time from the trading floor. While there has long been debate about the social and biological differences between men and women, new research by the Kellogg School of Management at Northwestern University, the University of Chicago Booth School of Business and the University of Chicago's Department of Comparative Human Development explores how the hormone testosterone plays an important role in gender differences in financial risk aversion and career choice. Prior research has shown that testosterone enhances competitiveness and dominance, reduces fear, and is associated with risky behaviors like gambling and alcohol use.
Springer, one of the leading publishers in the fields of science, technology and medicine, has signed an agreement with The Endocrine Society to co-publish a new journal, Hormones & Cancer, starting in January 2010. Hormonal cancers include two of the most deadly cancer subtypes, cancers of the breast and prostate. In addition to these cancers, Hormones & Cancer will include research articles covering other less-commonly occurring cancer subtypes, such as thyroid, gynecologic and pituitary cancer. The journal will help to bridge the gap between those working in the two often disconnected fields of endocrinology and cancer research. Hormones & Cancer will be a true translational journal, including basic scientific, epidemiological and clinical research papers.
Shire Completes Submission Of NDA For Velaglucerase Alfa For Type 1 Gaucher Disease And Reports Positive Results For Remaining Two Phase III Trials
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, reported that it has completed its submission of a New Drug Application (NDA) for velaglucerase alfa, its enzyme replacement therapy in development for the treatment of Type 1 Gaucher disease, with the U.S. Food and Drug Administration (FDA). The Company also announced positive results from the final two Phase III studies of velaglucerase alfa, with both studies reaching all of their primary and secondary endpoints. "The submission of the NDA for velaglucerase alfa, earlier than previously announced, is an important milestone for Shire, bringing us another step closer to providing a new treatment option for patients with Type 1 Gaucher disease, " said Sylvie Gregoire, President of Shire Human Genetic Therapies.
Breast cancer patients taking a long-term course of the estrogen-blocker tamoxifen, which has been used widely to prevent recurrences of hormone-sensitive breast cancer, might have four times the risk of developing "an uncommon but aggressive" new tumor that is not estrogen-sensitive, according to a new study published Tuesday in the journal Cancer Research, the New York Times reports. According to the Times, the study by Christopher Li -- an associate member of the Fred Hutchinson Cancer Research Center in Seattle -- and colleagues was an observational study and not a randomized, controlled clinical trial. For the study, the researchers analyzed medical histories of more than 1, 000 women who were diagnosed with estrogen-sensitive breast cancer between ages 40 and 79.
In the first study to look at what happens over the years to the billions of pounds of plastic waste floating in the world's oceans, scientists are reporting that plastics - reputed to be virtually indestructible - decompose with surprising speed and release potentially toxic substances into the water. Reporting here today at the 238th National Meeting of the American Chemical Society (ACS), the researchers termed the discovery "surprising." Scientists always believed that plastics in the oceans were unsightly, but a hazard mainly to marine animals that eat or become ensnared in plastic objects. "Plastics in daily use are generally assumed to be quite stable, " said study lead researcher Katsuhiko Saido, Ph.
Amgen Issues Statement On Outcomes Of Advisory Committee For Reproductive Health Drugs ACRHD Meeting
Amgen Inc. (Nasdaq: AMGN) issued the following statement on the outcome of today's meeting with the U.S. Food and Drug Administration (FDA) Advisory Committee for Reproductive Health Drugs (ACRHD) to review the potential use of Prolia(TM) (denosumab) for the prevention and treatment of postmenopausal osteoporosis and the prevention and treatment of bone loss in patients undergoing hormone ablation for either prostate cancer or breast cancer. After reviewing safety and efficacy data from 30 clinical studies involving more than 12, 000 patients, the Committee recommended approval of Prolia for the treatment of postmenopausal osteoporosis and for the treatment of bone loss in patients undergoing hormone ablation for prostate cancer.